目的 系统评价贞芪扶正制剂辅助化疗治疗肿瘤的疗效与安全性，为临床治疗提供循证参考。方法 计算机检索中文数据库中文学术期刊全文数据库（CNKI）、中国生物医学文献数据库（CBM）、万方数据库（WanFang Data）、维普中文期刊全文数据库（VIP）、PubMed、Cochrane图书馆有关贞芪扶正制剂辅助化疗治疗肿瘤的随机对照试验（RCT），检索时限为各数据库建库起至2021年3月。以Cochrane 5.3偏倚风险评估工具评价纳入文献质量，采用RevMan 5.3统计软件进行Meta分析。结果 共纳入33项RCTs，包括2 666例患者。Meta分析结果显示，贞芪扶正制剂辅助化疗治疗肿瘤能显著提高临床有效率［RR＝1.34，95% CI=（1.21，1.45），P<0.000 01］，同时还能改善患者生存质量［RR＝2.24，95% CI=（1.56，3.20），P<0.000 1］，提高患者免疫力，改善造血功能抑制，降低肝肾毒性等发生率，与对照组比较差异均有统计学意义。结论 贞芪扶正制剂辅助化疗治疗肿瘤的疗效与安全性均较好。

Objective To systematically review the efficacy and safety of Zhenqifuzheng preparation combined with chemotherapy in the treatment of cancer,and provide evidence-based reference for clinical treatment. Methods Computer searches of CNKI, CBM, WanFang, VIP, PubMed, and Cochrane Library were conducted to collect randomized controlled trials (RCTS) on ZhenqiFuzheng preparation combined with chemotherapy in the treatment of cancer, from the time of establishing database to May 2021. Quality evaluation was conducted by Cochrane 5.3 bias risk assessment tool, and Meta-analysis was conducted by RevMan 5.3 statistical software. Results A total of 33 RCTs were enrolled, including 2 666 patients. The results of Meta-analysis showed that Zhenqifuzheng preparation combined with chemotherapy in the treatment of tumor can significantly improve the effective rate [RR ＝ 1.34, 95%CI = (1.21, 1.45), P < 0.000 01], but also can improve the quality of life [RR ＝ 2.24, 95%CI = (1.56, 3.20), P < 0.000 1], enhance immunity, improve hematopoietic function inhibition, reduce the incidence of hepatorenal toxicity, the differences were statistically significant. Conclusion Zhenqifuzheng preparation combined with chemotherapy has good efficacy and safety in the treatment of cancer.

R286.91

西安交通大学第一附属医院科研发展基金资助项目（2020ZYTS-17）